Clinical trials: Herpes Simplex Type II
Genital Herpes Simplex Type 2
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
This study evaluates the reduction in viral shedding after vaccination with a new formulation of GEN-003 in subjects with genital HSV-2 infection.
- Trial name
- NCT02515175
- Testing
- Matrix-M2, GEN-003
- Where
- 8 sites in United States
- Volunteers
- 131 people
- Sponsor
- Genocea Biosciences, Inc.
Pancreatic Cancer
OH2 Oncolytic Viral Therapy in Pancreatic Cancer
This phase Ib/II study evaluates the safety and efficacy of OH2 in patients with locally advanced/metastatic pancreatic cancer who have failed first-line standard treatment.
- Trial name
- NCT04637698
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Genital Herpes
Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2
The purposes of this study are: To determine the accuracy of commercially available serologic assays in diagnosing patients with herpes simplex virus type 2 (HSV-2); To assess the sensitivity and specificity of the commerical…
- Trial name
- NCT01112956
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Uterine Cervical Neoplasms
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.
- Trial name
- CC-OV01 (NCT05393440)
- Testing
- BS-006
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhongnan Hospital
Kaposi Sarcoma
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Background: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus.
- Trial name
- NCT07308886
- Testing
- CYT107
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Hepatitis C Infection
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
The purpose of this study is to study the effects of valacyclovir on patients who have hepatitis C and antibodies to herpes simplex type-2. Herpes simplex type 2 is a virus which causes genital herpes.
- Trial name
- NCT01453075
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
HSV-2 Infection, Genital Herpes
The VIBLOK SAfety and perFormancE Trial
Genital herpes has a high prevalence in industrialized as well as developing countries. Genital herpes causes genital ulcers, increases risk for acquiring HIV infection, and may be transmitted mother to child during birth with…
- Trial name
- SAFE (NCT03080961)
- Testing
- VIBLOK barrier cream
- Where
- 3 sites in Netherlands
- Volunteers
- 82 people
- Sponsor
- CLJI Worldwide
Solid Tumor, Melanoma
OH2 Injection in Solid Tumors
This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma).
- Trial name
- NCT04386967
- Testing
- OH2 injection, Keytruda
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Recurrent Genital Herpes
Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes
To evaluate the efficacy of repeat-dose UB-621 for the recurrent genital HSV-2 infection To evaluate the safety and tolerance of repeat-dose UB-621 for the recurrent HSV-2 infection To evaluate the pharmacokinetics of repeat-dose…
- Trial name
- NCT04979975
- Testing
- UB-621 low-dose, UB-621 high-dose
- Volunteers
- 200 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
HIV, Hepatitis C
A Methadone Maintenance Treatment Outcome Study in Three Provinces in China
The primary goal of this PHE is to determine the effectiveness of a tailored education program for MMT service providers. It was to be evaluated through methadone dose levels prescribed to new patients after training completion.
- Conditions
- HIV, Hepatitis C, Syphilis, Herpes Simplex Type II
- Trial name
- NCT01315054
- Testing
- MMT provider dosage training, targeted counseling, national guidelines
- Where
- China
- Volunteers
- 4,258 people
- Sponsor
- Centers for Disease Control and Prevention
Glioma, Astrocytoma
Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
This clinical trial will study the safety and effectiveness of an engineered herpes virus, G207, administered directly into the brain of patients with recurrent brain cancer.
- Conditions
- Glioma, Astrocytoma, Glioblastoma
- Trial name
- NCT00028158
- Testing
- G207, an oncolytic virus
- Volunteers
- 65 people
- Sponsor
- MediGene
Genital Herpes
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
- Trial name
- NCT07330440
- Testing
- Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
HIV Infections, HSV-2 Infection
Immunogenetic Modulators of Mucosal Protection From HIV-1
This is a single site, prospective, observational study that seeks to assess changes in mucosal immunity that occur as a result of HIV-1 exposure, HSV-2 infection, and/or pre-exposure prophylaxis (PrEP) usage to prevent HIV-1…
- Trial name
- Kinga (NCT03701802)
- Where
- Kenya
- Volunteers
- 812 people, healthy volunteers welcome
- Sponsor
- University of Washington
Genital Herpes Simplex Type 2
Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study
This is a voluntary study to allow subjects who received placebo while on GEN-003-002 to be randomized, in a blinded manner, to 1 of 6 active combinations of GEN-003 and Matrix-M2.
- Trial name
- NCT02300142
- Testing
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg)
- Where
- 16 sites in United States
- Volunteers
- 37 people
- Sponsor
- Genocea Biosciences, Inc.
Hepatitis C Virus Infection, Infection
Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C
This trial is to determine the safety of valacyclovir in persons with chronic hepatitis C and herpes simplex type 2 infection. Participants will be randomized to valacyclovir or matching placebo.
- Conditions
- Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
- Trial name
- NCT01037621
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- G.V. (Sonny) Montgomery VA Medical Center
Genital Herpes Simplex Type 2
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.
- Trial name
- NCT02910284
- Testing
- Observational
- Where
- 13 sites in United States
- Volunteers
- 140 people
- Sponsor
- Genocea Biosciences, Inc.
Solid Tumor, Gastrointestinal Cancer
OH2 Oncolytic Viral Therapy in Solid Tumors
This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft…
- Trial name
- NCT03866525
- Testing
- OH2 injection, with or without irinotecan or HX008
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.